

Dear LuCIN Colleagues,

At Lupus Therapeutics, we are acutely aware of how challenging things must be at your institution in dealing with the COVID-19 pandemic. The impacts of the virus have been far more reaching than anticipated, putting at risk the ability to conduct patient care and clinical research.

As such, I wanted to follow-up to my March 12 note related to receiving information from LuCIN sites regarding strict policies that were being employed with respect to human subject research and related research visits.

In the interest of furthering assessing the impact of the virus on clinical trials being conducted at LuCIN sites, I had requested, if permissible, to share institutional policies/guidance documents or a link to such policies regarding the restrictions being employed at sites. I would like to thank the LuCIN sites that provided information to date.

The intent of collecting this information was to create an open "document warehouse" where such policies could be shared as a resource Network-wide as well as with our industry partners. At Lupus Therapeutics we feel that transparency and being a facilitator in sharing pertinent information related to the pandemic and its impact in conducting clinical research with our core constituents is important as we try to navigate these challenging and uncertain times together.

To this end, below is a link that I encourage you to access and share internally regarding measures that are being taken at other LuCIN sites. In addition, we have provided supplementary information as it relates to pertinent research and most recently, an FDA guidance publication with respect to conducting clinical research during the pandemic. We hope you find this information useful and perhaps insightful. We will continue to update the drive as new information is shared.

<https://drive.google.com/drive/folders/1MEJoKcoY9mXj3WtaQMH1-wNA8V6oQYB>

Finally, I encourage any LuCIN site that has not shared institutional published policies to date, to please reconsider doing so. These can be emailed directly to my colleague Ms. Marie Revers @ [mrevers@lupusresearch.org](mailto:mrevers@lupusresearch.org). We fully recognize these policies will likely change from day-to-day, but it would be very helpful and informative to have a current understanding of the implications COVID-19 is having across our Network and in the conduct of clinical research.

In the meantime, on behalf of the Lupus Research Alliance and Lupus Therapeutics, I want to thank each of you for everything you do to help protect and keep patients safe during these challenging and uncertain times. Most importantly, please take care of yourselves and families. This too will pass.

Warmly,  
AI

---

Albert T. Roy  
Executive Director  
Lupus Therapeutics, LLC  
2550 South Clark Street, Ste. 670  
Arlington, VA 22202  
Phone: 646.884.6071  
Email: [aroy@lupusresearch.org](mailto:aroy@lupusresearch.org)  
Website: [www.lupusresearch.org](http://www.lupusresearch.org)

